Drug intelligence / Profile preview

arginine + carvedilol

Development stage
Approved
Lead developer
Physician Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

**Arginine + carvedilol** is a combination product containing two active substances: L-arginine, a conditionally essential amino acid involved in nitric oxide (NO) synthesis, and carvedilol, a non-selective beta-adrenergic and alpha-1 adrenergic receptor antagonist (beta-blocker). This combination has been explored for potential synergistic effects in cardiovascular disease, particularly for *hypertension*, *left ventricular dysfunction*, and *heart failure*, as well as for reducing peptic ulcer severity and oxidative stress in experimental models. Arginine increases endogenous NO (vasodilator, gastroprotectant) and carvedilol reduces blood pressure and heart rate by blocking adrenergic receptors. The exact clinical efficacy and approval status of this specific combination is limited; one formulation under the brand HYPERTENEVIDE-12.5 was marketed by Physician Therapeutics in the US as an unapproved kit.

Brand names
HYPERTENEVIDE-12.5HYPERTENEVIDE12.5HYPERTENEVIDE 12.5
Other names
arginine and carvedilol
02

Targets

ADRA2A (α2A)ADRA1D (α1D)NOS1 (nNOS)ADRA1B (α1B)ADRA1A (α1A)ADRB1 (β1)

Beyond the preview

Go deeper on arginine + carvedilol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on arginine + carvedilol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call